Publication date: Available online 22 November 2018
Source: Journal of Allergy and Clinical Immunology
Author(s): Raffaela Campana, Katharina Marth, Petra Zieglmayer, Milena Weber, Christian Lupinek, Yury Zhernov, Olga Elisyutina, Musa Khaitov, Eva Rigler, Kerstin Westritschnig, Uwe Berger, Martin Wolkersdorfer, Fritz Horak, Friedrich Horak, Rudolf Valenta
Summary
This is the first double-blind, placebo-controlled study showing that vaccination with recombinant hypoallergenic allergen-derivatives is safe and induces sustained allergen-specific IgG responses which block allergic patients IgE binding to the allergen.
from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Ks2PXn
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.